CDK4 and neoplasm: Other studies have shown that miR-486 can mediate tumor-suppressive effects by targeting fibrillin 1 in papillary thyroid carcinoma (28), by targeting CDK4/BCAS2 protein in esophageal cancer (29), and by targeting the insulin-like growth factor 1 receptor and its downstream effectors, the mammalian target of rapamycin, the signal transducer, and activator of transcription 3 and c-Myc, in hepatocellular carcinoma (30).